Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1)

被引：0
|
作者：
Bolli, G. [1 ]
Munteanu, M. [2 ]
Dotsenko, S.
Niemoeller, E. [3 ]
Boka, G. [4 ]
Hanefeld, M. [5 ]
机构：
[1] Univ Perugia, I-06100 Perugia, Italy
[2] Univ Med & Farm Timisoara, Timisoara, Romania
[3] Sanofi Aventis, Frankfurt, Germany
[4] Sanofi Aventis, Chilly Mazarin, France
[5] GWT TUD GmbH, Ctr Clin Studies, Dresden, Germany
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
784
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
    Bolli, G. B.
    Munteanu, M.
    Dotsenko, S.
    Niemoeller, E.
    Boka, G.
    Wu, Y.
    Hanefeld, M.
    DIABETIC MEDICINE, 2014, 31 (02) : 176 - 184
  • [2] Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S)
    Ratner, R. E.
    Hanefeld, M.
    Shamanna, P.
    Min, K.
    Boka, G.
    Miossec, P.
    Muehlen-Bartmer, I.
    Rosenstock, J.
    DIABETOLOGIA, 2011, 54 : S317 - S317
  • [3] Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-X)
    Rosenstock, J.
    Raccah, D.
    Koranyi, L.
    Maffei, L.
    Boka, G.
    Miossec, P.
    Gerich, J. E.
    DIABETOLOGIA, 2011, 54 : S317 - S318
  • [4] Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
    Pinget, M.
    Goldenberg, R.
    Niemoeller, E.
    Muehlen-Bartmer, I.
    Guo, H.
    Aronson, R.
    DIABETES OBESITY & METABOLISM, 2013, 15 (11) : 1000 - 1007
  • [5] Efficacy and Safety of Lixisenatide Once Daily Versus Placebo in Patients With Type 2 Diabetes Insufficiently Controlled on Pioglitazone (GetGoal-P)
    Pinget, Michel
    Goldenberg, Ronald
    Niemoeller, Elisabeth
    Muehlen-Bartmer, Isabel
    Aronson, Ronnie
    DIABETES, 2012, 61 : A258 - A258
  • [6] Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
    Pinget, M.
    Goldenberg, R.
    Niemoeller, E.
    Muehlenbartmer, I.
    Aronson, R.
    DIABETOLOGIA, 2012, 55 : S334 - S334
  • [7] Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin ± metformin: GetGoal-L study
    Aronson, R.
    Riddle, M.
    Home, P.
    Marre, M.
    Niemoeller, E.
    Ping, L.
    Rosenstock, J.
    DIABETOLOGIA, 2012, 55 : S8 - S8
  • [8] Efficacy and Safety of Once-Daily Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Basal Insulin ± Metformin: GetGoal-L Study
    Riddle, Matthew
    Home, Philip
    Marre, Michel
    Niemoeller, Elisabeth
    Ping, Lin
    Rosenstock, Julio
    DIABETES, 2012, 61 : A251 - A251
  • [9] Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
    Ahren, Bo
    Leguizamo Dimas, Aniceto
    Miossec, Patrick
    Saubadu, Stephane
    Aronson, Ronnie
    DIABETES CARE, 2013, 36 (09) : 2543 - 2550
  • [10] Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
    Kapitza, C.
    Forst, T.
    Coester, H. -V.
    Poitiers, F.
    Ruus, P.
    Hincelin-Mery, A.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07) : 642 - 649
12345